Kamada (KMDA) Cash from Investing Activities (2013 - 2026)
Kamada's (KMDA) quarterly Cash from Investing Activities came in at -$41.2 million in Q1 2026, down 2721.78% YoY from $1.6 million in Q1 2025, and down 1384.61% on a QoQ basis from -$2.8 million in Q4 2025.
Kamada (KMDA) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Kamada (KMDA) has 14 years of Cash from Investing Activities data on file, last reported at -$41.2 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 2721.78% year-over-year to -$41.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49.6 million (down 420.92% YoY) and the FY2025 annual result came in at -$9.8 million, up 8.39% from the prior year.
- Cash from Investing Activities retreated to -$41.2 million in Q1 2026, from -$2.8 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$1093.0 in Q1 2023 to a low of -$41.2 million in Q1 2026.
- A 5-year average of -$4.0 million and a median of -$2.0 million in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 99.79% — and 2024, when it slumped 245279.69%.
- Tracing KMDA's Cash from Investing Activities over 5 years: stood at -$977000.0 in 2022, then plunged by 101.94% to -$2.0 million in 2023, then slumped by 48.2% to -$2.9 million in 2024, then grew by 5.1% to -$2.8 million in 2025, then tumbled by 1384.61% to -$41.2 million in 2026.
- The last three Cash from Investing Activities figures came in at -$41.2 million (Q1 2026), -$2.8 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Kamada | 459.44 Mn | 429.97 Mn | 22.47 Mn | -2.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.54 Mn |
| Jun 30, 2026 | -2.54 Mn |
| Mar 31, 2026 | -41.20 Mn |
| Mar 31, 2026 | -41.20 Mn |
| Dec 31, 2025 | -2.78 Mn |
| Dec 31, 2025 | -2.78 Mn |
| Sep 30, 2025 | -3.59 Mn |
| Sep 30, 2025 | -3.59 Mn |
| Jun 30, 2025 | -2.01 Mn |
| Jun 30, 2025 | -2.01 Mn |
| Mar 31, 2025 | -1.46 Mn |
| Mar 31, 2025 | -1.46 Mn |
| Dec 31, 2024 | -2.92 Mn |
| Dec 31, 2024 | -2.92 Mn |
| Sep 30, 2024 | -2.12 Mn |
| Sep 30, 2024 | -2.12 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Mar 31, 2024 | -2.68 Mn |
| Mar 31, 2024 | -2.68 Mn |